Sun Pharma posts Q1 profit on strong US sales

Tags: Companies
Sun Pharmaceutical Industries Ltd, India's largest drugmaker by market value, reported a better-than-expected first-quarter profit, reflecting higher sales in its largest market, the United States.

April-June net profit was 13.91 billion rupees ($227.73 million), compared with a net loss of 12.76 billion rupees a year earlier. The prior-year period included a 25.17 billion rupee provision for settlement of a patent infringement litigation.

Analysts on average had expected a profit of 12.85 billion rupees, according to data compiled by Thomson Reuters.

Net sales rose 12 percent to 39.36 billion rupees, while sales in the United States, from where the company makes more than half its revenue, advanced 7 percent.

Sun Pharma is in the process of gaining regulatory approvals for its $3.2 billion acquisition of loss-making rival Ranbaxy Laboratories Ltd from Japan's Daiichi Sankyo Ltd and expects to close the deal by December.

The company has got approvals for the deal from anti-competition authorities in all applicable markets excluding India and the United States, Sun Pharma said in a statement late on Tuesday.

EDITORIAL OF THE DAY

  • Do we need a new yardstick to gauge our prosperity?

    While we in India are trying to clear the cobwebs of confusion about how best to calculate gross domestic product (GDP) growth statistics, at the best

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Susan Visvanathan

A world that is constantly at war

THE 19th century posed specific problems to theorists about how ...

Rajgopal Nidamboor

Let’s find the power within & transform

It goes without saying that we are in the midst ...

Shona Adhikari

Masterpieces on the auction block

A rather important auction of 20th century Indian art by ...